Skip to main content

MenHibrix Side Effects

Generic name: haemophilus b conjugate (prp-t) vaccine / meningococcal conjugate vaccine

Medically reviewed by Drugs.com. Last updated on Oct 23, 2022.

Note: This document contains side effect information about haemophilus b conjugate (prp-t) vaccine / meningococcal conjugate vaccine. Some dosage forms listed on this page may not apply to the brand name MenHibrix.

Applies to haemophilus b conjugate (prp-t) vaccine/meningococcal conjugate vaccine: intramuscular powder for injection.

Nervous system

Very common (10% or more): Drowsiness

Postmarketing reports: Febrile seizures, hypotonia, headache, dizziness[Ref]

Other

Very common (10% or more): Fever (rectal 38C or higher)

Uncommon (0.1% to 1%): Fever (rectal over 39.5C)

Rare (less than 0.1%): Malaise[Ref]

Metabolic

Very common (10% or more): Decreased appetite[Ref]

Local

Very common (10% or more): Injection site reaction (swelling, pain, redness)

Common (1% to 10%): Injection site reactions including induration and nodules[Ref]

Psychiatric

Very common (10% or more): Irritability

Uncommon (0.1% to 1%): Crying

Rare (less than 0.1%): Insomnia[Ref]

Respiratory

Postmarketing reports: Apnea in very premature infants (28 weeks gestation or less)[Ref]

Gastrointestinal

Uncommon (0.1% to 1%): Diarrhea, vomiting

Rare (less than 0.1%): Abdominal pain[Ref]

Dermatologic

Uncommon (0.1% to 1%): Atopic dermatitis, rash[Ref]

Hematologic

Postmarketing reports: Lymphadenopathy[Ref]

Hypersensitivity

Postmarketing reports: Allergic reactions (including urticaria and anaphylactoid reactions)[Ref]

More about MenHibrix (haemophilus b conjugate (prp-t) vaccine / meningococcal conjugate vaccine)

Patient resources

Related treatment guides

References

1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.